Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s traded shares stood at 0.89 million during the last session, with the company’s beta value hitting 0.96.The MREO share’s 52-week high remains $5.02, putting it -14.09% down since that peak but still an impressive 73.64% since price per share fell to its 52-week low of $1.16. The company has a valuation of $676.54M, with an average of 0.67 million shares in intraday trading volume over the past 10 days and average of 904.82K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Mereo Biopharma Group Plc ADR (MREO), translating to a mean rating of 1.20. Of 2 analyst(s) looking at the stock, 0 analyst(s) give MREO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.02.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
The 5-day price performance for the stock is 6.28%, and -0.68% over 30 days. With these gigs, the year-to-date price performance is 90.48%. Short interest in Mereo Biopharma Group Plc ADR (NASDAQ:MREO) saw shorts transact 4.54 million shares and set a 5.01 days time to cover.
The extremes give us $4 and $8 for target low and target high price respectively. As such, MREO has been trading -81.82% off suggested target high and 9.09% from its likely low.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
The rating firms project that company’s revenue will grow 39.20% compared to the previous financial year.
Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 14.19M.
MREO Dividends
Mereo Biopharma Group Plc ADR has its next earnings report out on 2024-Aug-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Mereo Biopharma Group Plc ADR insiders hold 1.08% of total outstanding shares, with institutional holders owning 65.49% of the shares at 66.20% float percentage. In total, 65.49% institutions holds shares in the company, led by RUBRIC CAPITAL MANAGEMENT LP. As of 2024-06-30, the company held over 15.31 million shares (or 2.1859% of shares), all amounting to roughly $55.11 million.
The next major institution holding the largest number of shares is ADAGE CAPITAL PARTNERS GP, L.L.C. with 11.79 million shares, or about 1.6838% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $42.45 million.
